House Appropriations Bills Include Increased Federal Funding for ID Programs
IDSA is pleased to see increased funding to strengthen the federal response to antimicrobial resistance, bolster the domestic and global fight against COVID-19, combat the infectious diseases impacts of the opioid crisis and strengthen global security in two recently passed appropriations bills. While even deeper investments are needed in many of these areas, funding allocated in the House Labor, Health and Human Services appropriations bill passed on June 29 and the State and Foreign Operations appropriations bill passed on June 28 will drive meaningful progress towards tackling our nation’s health challenges.
The Society is grateful to the LHHS Subcommittee and full Committee Chair Rosa DeLauro (D-CT), full Committee Ranking Member Kay Granger (R-TX), SFOPs Chairwoman Barbara Lee (D-CA), SFOPs Ranking Member Hal Rogers (R-KY) and LHHS Ranking Member Tom Cole (R-OK) for providing these vital program increases. We deeply appreciate the continued leadership of Reps. Chellie Pingree (D-ME) and Buddy Carter (R-GA) in leading a bipartisan letter, signed by 59 representatives, calling for significant new investments to combat AMR.
As the appropriations process moves forward to the Senate, IDSA continues to urge congressional appropriators to increase funding in FY 2023 for infectious diseases programs that will enable us to meet the historic challenges we face with resources commensurate with the tasks ahead.
Labor, Health and Human Services Appropriations Bill
- The bill includes a total of $10.4 billion for CDC, an increase of $2 billion above the FY 2022 enacted level and $1 billion above the President’s budget request.
- $202 million for CDC’s Antibiotic Resistance Solutions Initiative, a $20 million increase over FY 2022
- $31 million in funding for the National Healthcare Safety Network at CDC, a $10 million increase over FY 2022
- $50 million in funding for the Advanced Molecular Detection initiative at CDC, a $15 million increase over FY 2022
- $825 million for CDC’s Immunization Program, a $175 million increase over FY 2022
- $65 million for CDC’s Quarantine Program, a $15 million increase over FY 2022
- $43 million for infectious diseases and opioid activities at CDC, $25 million increase over FY 2022
- $1.463 billion in funding for the Division of HIV, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis, a $118 million increase over FY 2022
- $6.642 billion to the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, a $320 million increase over FY 2022, including $560 million for antibiotic resistance research at NIAID, an increase of $20 million over FY 2022
- $845 million for the Biomedical Advanced Research and Development Authority, a $100 million increase over FY 2022 funding
- $757 million, an increase of $111 million above FY 2022, for the Center for Global Health, which includes $353 million for global health security, a $100 million increase
- $99 million to NIH’s John C. Fogarty International Center, $12 million over FY 2022 funding
- $250 million, an increase of $150 million above FY 2022, to modernize public health data surveillance and analyticsat CDC and state and local health departments
State and Foreign Operations Appropriations Bill
- $1 billion for global health security, an increase of $300 million, to prevent future pandemics through both bilateral and multilateral mechanisms
- $2 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria, a $440 million increase to support a strong U.S. commitment to the seventh replenishment of the Global Fund in support of the goal of ending the epidemics of AIDS, TB and malaria
- $4.395 billion for the President’s Emergency Plan for AIDS Relief, a $5 million increase
- $469 million for the USAID global TB program, an increase of almost $100 million over FY 2022 funding